Muscle volume loss after the induction of first-line chemotherapy as a novel prognostic factor in metastatic colorectal cancer patients

被引：0

作者：

Yoshikawa, Yusuke ^{[1
]}

Okabayashi, Koji ^{[1
]}

Hasegawa, Hirotoshi ^{[1
]}

Tsuruta, Masashi ^{[1
]}

Seishima, Ryo ^{[1
]}

Takahashi, Hidena ^{[1
]}

Yamada, Toru ^{[1
]}

Matsui, Shimpei ^{[1
]}

Kondo, Takayuki ^{[1
]}

Shimada, Takehiro ^{[1
]}

Matsuda, Mutsuhito ^{[1
]}

Yahagi, Masashi ^{[1
]}

Asada, Yusuke ^{[1
]}

Sugiura, Kiyoaki ^{[1
]}

Suzuki, Yoshiyuki ^{[1
]}

Tajima, Yuki ^{[1
]}

Nakadai, Junpei ^{[1
]}

Kitagawa, Yuko ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期

关键词：

D O I：

10.1200/jco.2015.33.3_suppl.558

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

558

引用

页数：1

共 50 条

[21] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
Ubago, R.
Castillo, M. A.
Flores, S.
Beltran, C.
VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
[22] Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer
Puthillath, Ajithkumar
Dunn, Kelli Bullard
Rajput, Ashwani
Smith, Judy
Yang, Gary
Wilding, Gregory E.
Tan, Wei
Gupta, Bhavna
Fakih, Marwan G.
CLINICAL COLORECTAL CANCER, 2007, 6 (10) : 710 - 715
[23] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
Xiong, Lifeng
Lou, Yinmei
Wang, Lin
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
[24] FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
Aparicio, Jorge
Fernandez-Martos, Carlos
Vicent, Jose M.
Maestu, Inmaculada
Llorca, Cristina
Busquier, Isabel
Campos, Jan M.
Perez-Enguix, Daniel
Balcells, Miquel
CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 263 - 267
[25] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Shun Yamamoto
Kengo Nagashima
Takeshi Kawakami
Seiichiro Mitani
Masato Komoda
Yasushi Tsuji
Naoki Izawa
Kentaro Kawakami
Yoshiyuki Yamamoto
Akitaka Makiyama
Kentaro Yamazaki
Toshiki Masuishi
Taito Esaki
Takako Eguchi Nakajima
Hiroyuki Okuda
Toshikazu Moriwaki
Narikazu Boku
BMC Cancer, 21
[26] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Yamamoto, Shun
Nagashima, Kengo
Kawakami, Takeshi
Mitani, Seiichiro
Komoda, Masato
Tsuji, Yasushi
Izawa, Naoki
Kawakami, Kentaro
Yamamoto, Yoshiyuki
Makiyama, Akitaka
Yamazaki, Kentaro
Masuishi, Toshiki
Esaki, Taito
Nakajima, Takako Eguchi
Okuda, Hiroyuki
Moriwaki, Toshikazu
Boku, Narikazu
BMC CANCER, 2021, 21 (01)
[27] No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
Antoun, Sami
Bayar, Mohamed Amine
Dyevre, Valerie
Lanoy, Emilie
Smolenschi, Cristina
Ducreux, Michel
BMC CANCER, 2019, 19 (01)
[28] No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
Sami Antoun
Mohamed Amine Bayar
Valérie Dyevre
Emilie Lanoy
Cristina Smolenschi
Michel Ducreux
BMC Cancer, 19
[29] First-line treatment options for patients with metastatic colorectal cancer
Richard L Schilsky
Nature Clinical Practice Oncology, 2004, 1 : 70 - 71
[30] First-line treatment options for patients with metastatic colorectal cancer
Schilsky, Richard L.
NATURE CLINICAL PRACTICE ONCOLOGY, 2004, 1 (02): : 70 - 71

← 1 2 3 4 5 →